Aduhelm Approval Boosts Other Alzheimer’s Drug Developers
Even Companies Not Focused On Clearing Amyloid Benefitted
Executive Summary
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
You may also be interested in...
Muna Launches On 'Rising Tide' Of Alzheimer's
Backed by investors such as Sofinnova, Polaris and Sanofi Ventures, Muna has assembled a strong team dedicated to developing small molecules to repair neuronal dysfunction and resolve neuroinflammation.
Denovo Dusts Down Lundbeck's Failed Alzheimer's Drug
The Danish group put the 5-HT6 antagonist on the shelf after three failed late-stage trials but Denovo believes that idalopirdine could still work for a subset of Alzheimer's patients.
GSK Looks To Immuno-Neurology In $700m Alector Tie-up
Alector says upfront payment and earnouts will fully pay for development of AL101 and AL001 in frontotemporal dementia and indications including ALS, Alzheimer’s and Parkinson’s.